March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
Feb. 20, 2020: Protease inhibitors and heart attack risk; HIV status and pericardial adipose tissue volume; cardiovascular risk profiles on TDF vs. TAF; hemostatic profiles in older people living with HIV.
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
June 27, 2019: Long-term viability of NRTI-free salvage therapy; factors associated with HIV treatment interruption; evolution of frailty risk among older people; skin and soft tissue infections among people with HIV.
The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
A recent study linked more cognitive activity to better cognitive performance in older African Americans with HIV infection.
Women with HIV tend to perform worse than HIV-negative women on cognitive performance tests, even after many years on treatment, new research finds -- but trends differed depending on the test and on women's treatment success.